First-line treatment
For adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations
FIRST-LINE TREATMENT WITH RYBREVANT®:
A POWERFUL* & TARGETED COMBINATION1
RYBREVANT® in combination with carboplatin and pemetrexed (chemotherapy) is the only first-line targeted treatment to improve PFS vs chemotherapy alone, with a 60% reduction in risk of progression or death1,2
*HR=0.40 (95% CI: 0.30, 0.53; P<0.0001); mPFS: 11.4 months (95% CI: 9.8, 13.7) vs 6.7 months (95% CI: 5.6, 7.3), respectively.
Discover how RYBREVANT®
may benefit your patients
RYBREVANT® is also approved for patients with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.1
CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; MOA, mechanism of action; mPFS, median progression-free survival; NSCLC, non-small cell lung cancer; PFS, progression-free survival.
Register for Updates
Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.
References
1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
2. The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen submits supplemental biologics license application to the US Food and Drug Administration seeking approval of RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Accessed February 14, 2024. https://www.prnewswire.com/news-releases/janssen-submits-supplemental-biologics-license-application-to-the-us-food-and-drug-administration-seeking-approval-of-rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-for-the-first-line-treatment-of-patients-with-l-301910074.html